Related Experiment Video
Updated: Jun 22, 2026
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Localized dyskeratotic plaque with milia associated with sorafenib
Jeaneen A Chappell1, Nicole M Burkemper, Natalie Semchyshyn
1Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri 63104, USA.
Abstract:
Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005. Since its introduction to the market, there have been various dermatologic side effects reported in the literature, the most well known being hand-foot skin reaction. This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.
Insights
Sorafenib therapy can cause skin reactions beyond the common hand-foot syndrome. This case highlights an unusual, localized rash with a prolonged resolution time, expanding knowledge of sorafenib
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Sorafenib is a FDA-approved kinase inhibitor for hepatocellular carcinoma and renal cell carcinoma.
- Dermatologic side effects are common with sorafenib, most notably hand-foot skin reaction.
- Understanding the full spectrum of sorafenib-induced cutaneous reactions is crucial for patient management.
Observation:
- This report details a patient experiencing an atypical, localized cutaneous eruption during sorafenib treatment.
- The observed rash presented with an unusual clinical course.
- The eruption demonstrated a protracted resolution time, lasting longer than typical reactions.
Findings:
- The case illustrates a rare and atypical skin reaction to sorafenib.
- The localized nature and prolonged course differentiate this eruption from common sorafenib dermatopathies.
- This presentation expands the known dermatologic adverse events associated with sorafenib therapy.
Implications:
- Clinicians should be aware of diverse and atypical skin reactions to sorafenib.
- Prompt recognition and management of unusual cutaneous eruptions can improve patient outcomes.
- Further research into the mechanisms of rare sorafenib-induced dermatologic toxicities is warranted.
